Q-omics provides the consensus-scored ANKRD55 profile across patient tissues and cancer cell-line models. ANKRD55 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ANKRD55 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, ANKRD55 RNA expression shows 15,908 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KICH, and UVM as cancer lineages where ANKRD55 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD55 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD55 survival associations across molecular data types. ANKRD55 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD55 RNA expression–survival associations across cancer types. High ANKRD55 expression shows unfavorable associations in UCS, but favorable associations in LUAD, HNSC, BRCA, CESC and SKCM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ANKRD55 RNA expression.
This table summarizes ANKRD55 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD55. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD55 shows lower tumor expression in KICH, COAD, HNSC, LIHC, LUSC and KIRP. The KICH box plot shows higher ANKRD55 RNA expression in normal versus tumor tissue (log2 FC = −0.650, t-test p < 0.001).
This table shows molecular features associated with ANKRD55 in patient tissues and cancer cell lines. In patient samples, ANKRD55 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD55 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
